TCIM
TARA icon

TIAA CREF Investment Management’s Protara Therapeutics TARA Stock Holding History

TIAA CREF Investment Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-496
Closed -$154K – 3185
2016
Q1 		$154K Hold
496
– – ﹤0.01% 3011
2015
Q4 		$308K Hold
496
– – ﹤0.01% 3010
2015
Q3 		$276K Hold
496
– – ﹤0.01% 3003
2015
Q2 		$354K Buy
+496
New +$307K ﹤0.01% 3042

Other funds holding TARA

TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

TIAA CREF Investment Management's TARA Position: Q2 2016 in Review

TIAA CREF Investment Management sold out of Protara Therapeutics (TARA) in Q2 2016, closing a stake of 496 shares — an estimated $154K sold.

TIAA CREF Investment Management first reported a position in TARA in Q2 2015 and held it in 4 quarters. The position peaked at $354K in Q2 2015. 32 funds tracked by Wall St. Rank hold TARA as of Q2 2016.

  • TIAA CREF Investment Management reported no remaining Protara Therapeutics position as of Q2 2016 after selling out during the quarter.
  • TIAA CREF Investment Management sold 496 Protara Therapeutics shares in Q2 2016, an estimated $154K.
  • TIAA CREF Investment Management first reported a position in Protara Therapeutics in Q2 2015 and held it in 4 quarters.
  • TIAA CREF Investment Management's Protara Therapeutics position peaked at $354K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2016.

Based on TIAA CREF Investment Management's 13F filing for Q2 2016, filed 11 Aug 2016.